

RESEARCH



# Identifying patients with Lynch syndrome using a universal tumor screening program in an integrated healthcare system

Philip R. Crain<sup>1</sup>, Jamilyn M. Zepp<sup>2</sup>, Sara Gille<sup>3</sup>, Lindsay Jenkins<sup>3</sup>, Tia L. Kauffman<sup>2</sup>, Elizabeth Shuster<sup>3</sup>, Katrina A.B. Goddard<sup>2</sup>, Benjamin S. Wilfond<sup>4</sup> and Jessica Ezzell Hunter<sup>2\*</sup>

## Abstract

**Introduction:** Lynch syndrome (LS) is associated with an increased risk of colorectal (CRC) and endometrial (EC) cancers. Universal tumor screening (UTS) of all individuals diagnosed with CRC and EC is recommended to increase identification of LS. Kaiser Permanente Northwest (KPNW) implemented a UTS program for LS among individuals newly diagnosed with CRC in January 2016 and EC in November 2016. UTS at KPNW begins with immunohistochemistry (IHC) of tumor tissue to determine loss of mismatch repair proteins associated with LS (MLH1, MSH2, MSH6, and PMS2). IHC showing loss of MLH1 is followed by reflex testing (automatic testing) to detect the presence of the *BRAF* V600E variant (in cases of CRC) and *MLH1* promoter hypermethylation to rule out likely sporadic cases.

**Materials and methods:** Individuals newly diagnosed with CRC and EC were identified between the initiation of the respective UTS programs and July 2018. Electronic medical records were reviewed to extract patient data related to UTS, including IHC and reflex testing results, date of referrals to the genetics department, and results of germline genetic testing for LS.

**Results:** 313 out of 362 individuals diagnosed with CRC and 61 out of 64 individuals diagnosed with EC who were eligible were screened by IHC for LS. Most (47/52 or 90%, including 46/49 CRC and 1/3 EC) individuals that were not screened by IHC only had a biopsy sample available. Fourteen individuals (3.7% overall, including 13/313 CRC and 1/61 EC) received an abnormal result after reflex testing and were referred for genetic counseling. Of these, 10 individuals (71% overall, including 9/13 CRC and 1/1 EC) underwent germline genetic testing for LS. Five individuals diagnosed with CRC were found to have pathogenic variants in *PMS2* ( $n = 3$ ), *MLH1* ( $n = 1$ ), and *MSH6* ( $n = 1$ ). No pathogenic variants were identified in individuals diagnosed with EC.

**Conclusions:** UTS identified individuals at risk for LS. Most individuals who screened positive for LS had follow-up germline genetic testing for LS. The consistent use of biopsy samples is an opportunity to improve UTS.

**Keywords:** Lynch syndrome, HNPCC, Colorectal cancer, Genetic screening, Genetic testing, Microsatellite instability

\* Correspondence: [Jessica.E.Hunter@kpchr.org](mailto:Jessica.E.Hunter@kpchr.org)

<sup>2</sup>Department of Translational and Applied Genomics, Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA  
Full list of author information is available at the end of the article



© The Author(s). 2022 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Introduction

Lynch syndrome (LS) is a hereditary cancer syndrome which notably leads to an increased risk of colorectal cancer (CRC) and endometrial cancer (EC), among many other cancer types. Males diagnosed with LS have a lifetime risk of 30–75% for CRC, while females diagnosed with LS face a lifetime risk of 25–50% for CRC and 30–40% for EC. [1] LS accounts for 3% of all cases of CRC and 2% of all cases of EC. [2–4] This autosomal dominant condition is caused by pathogenic variants in DNA mismatch repair (MMR) genes (*MLH1*, *MSH2*, *MSH6*, or *PMS2*) [5, 6] and deletions in *EPCAM* which result in inactivation of *MSH2*. [7, 8] Despite a prevalence estimate of 1 in 279 for LS in the United States general population, less than 2% of people affected by LS have been diagnosed. [9, 10] Undiagnosed individuals represent a missed opportunity to implement medical interventions to reduce cancer-related morbidity and mortality, including increased surveillance and risk-reducing surgery or medication. [1, 11, 12]

One approach to identify cases of LS focuses on the presence of high-risk criteria, such as a personal and family history, or early age at onset, of LS-associated cancers. [13] The Revised Amsterdam and Bethesda criterias [14–17] and risk assessment algorithms, such as PREMM<sub>5</sub>, MMRpro, and MMRpredict, [18–20] are examples of this approach to identify individuals appropriate for germline genetic testing for LS. However, this approach will miss LS in individuals who have limited or unreliable family history, do not meet the high-risk criteria, [21, 22] or meet the high-risk criteria but do not undergo genetic counseling and germline genetic testing for LS. [23–28] Universal tumor screening (UTS) for LS is a different approach to identifying individuals at heightened risk for LS. This approach includes all individuals newly diagnosed with CRC and EC, regardless of family history or age. Identification of individuals at heightened risk based upon cancer diagnosis as opposed to other risk criteria may lead to LS diagnoses in individuals who would otherwise be missed. UTS is recommended by multiple expert guidelines to increase the identification of LS. [13, 29–34]. Though the exact approach for UTS may vary across health care systems, the first step is typically screening tumor tissue with a test for, (microsatellite instability (MSI) or with immunohistochemistry (IHC) testing) to detect the absence of one or more of the MMR proteins (*MLH1*, *MSH2*, *MSH6*, and *PMS2*). Reflex testing follows if *MLH1* loss is reported to detect the presence of *BRAF* V600E or *MLH1* promoter hypermethylation, two indicators of sporadic *MLH1* loss unrelated to LS. Individuals that screen positive for LS (loss of one or more of the MMR proteins is detected and sporadic indicators are not found) after these steps are then referred

for genetic counseling and germline genetic testing to confirm an LS diagnosis. [4]

UTS has been implemented into many healthcare systems, but its uptake is still limited. Many barriers exist for healthcare systems to implement effective UTS programs. [35–37] Additionally, there are limited data on the outcomes of UTS in community healthcare settings, including measures of uptake of genetic counseling and germline genetic testing for LS. While there is substantial evidence to support UTS as valuable for identifying cases of LS, mixed results have been reported even in healthcare systems and regions similar to Kaiser Permanente Northwest (KPNW). [38, 39]

The goal of this study was to assess the effectiveness of a UTS program implemented by an integrated healthcare system by systematically determining whether all tumors from individuals with CRC and EC that should be screened with IHC were screened and to assess the rate of appropriate follow-up with the genetics department. This study adds to the evidence about UTS by detailing the flow of patients through the UTS process to identify points in the process that could be improved to maximize the effectiveness of UTS in identifying individuals with LS.

## Materials and methods

### Study population

KPNW serves more than 625,000 of the nearly 3,400,000 people in northwest Oregon and southwest Washington. KPNW is an integrated health care system, which is a membership-based, prepaid, direct health care system where members have access to care and services that are coordinated across inpatient and outpatient settings, pharmacy, lab, imaging, and other ancillary services. KPNW began to perform UTS among all individuals newly diagnosed with CRC in January 2016 and all individuals newly diagnosed with EC in November 2016.

### Universal tumor screening protocol

According to the UTS protocol at KPNW, each CRC and EC is tested by immunohistochemistry (IHC) to detect the presence or absence of the 4 MMR proteins: *MLH1*, *MSH2*, *MSH6*, or *PMS2*. If loss of *MLH1* is detected, reflex testing is performed. For CRC tumors, reflex testing starts with testing for the presence of *BRAF* V600E, followed by testing for *MLH1* hypermethylation if *BRAF* V600E is absent. For EC tumors, reflex testing consists of testing for *MLH1* hypermethylation only. The presence of *BRAF* V600E or *MLH1* hypermethylation indicate likely non-inherited (sporadic) tumor development, meaning an LS diagnosis in these individuals is atypical and genetic counseling and germline genetic testing for LS is not indicated. Individuals with MMR loss detected through IHC, and absence of *BRAF* V600E

and/or *MLH1* hypermethylation for individuals with detected *MLH1* loss, are referred to the genetics department for follow-up. Patients meet with a genetic counselor to discuss LS, their risk, and diagnostic testing is ordered, if indicated. Germline genetic testing is typically performed using a comprehensive panel of cancer risk genes. Test results are disclosed by the genetic counselor.

#### EMR review

The KPNW Tumor Registry was searched for all diagnoses of CRC (ICD-10 diagnosis codes: C18.0, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19.9, C20.9, and C21.8) and EC (ICD-10 diagnosis code: C54.1) between 2016 and July 2018. We excluded individuals who opted to have their medical data excluded from all types of research and individuals who opted to be excluded from genetics research. Electronic medical record (EMR) review of each case was performed by a study genetic counselor (JZ) to extract patient data related to UTS: date of birth, date of biopsy and/or surgery, results of IHC performed on tumor tissue, results of reflex testing, date of referrals to genetics department, date of encounters with genetics department, date germline genetic testing ordered, and results of germline genetic testing. For patients who underwent germline genetic testing and received a diagnosis of LS, notes captured during the genetic counseling session on personal and family history as well as pathology reports were used to assess whether the patient met Bethesda Guidelines [16, 17] or Amsterdam criteria [14, 15]. This analysis was approved by the Institutional Review Board at KPNW.

#### Statistical analysis

Detection rates for LS in CRC samples were calculated along with the associated 95% Wilson score confidence intervals.

## Results

#### Universal tumor screening in CRC patients

The screening and referral process of patients diagnosed with CRC are summarized in Figs. 1 and 2.


Of the 362 individuals eligible for UTS, 49 were not screened by IHC. Most of the individuals not screened by IHC (46/49 or 94%) only had biopsy samples available. However, 78 of the 313 who were screened by IHC also only had a biopsy sample available. This indicates there was inconsistent use of biopsy samples for screening by IHC when tumor resections were not available.

Overall, among the nine individuals who were referred to genetics after screening positive for LS, seven (78%) followed up with genetics. Of the seven individuals that followed up with genetics after a referral based on IHC results, six had germline genetic testing for LS, and one

individual who was found to have received a diagnosis of LS previously was not retested. Five (83%) of the six individuals who had germline genetic testing for LS had a subsequent diagnosis of LS. One additional individual was diagnosed with LS from the four individuals who screened positive but were referred prior to IHC results. These four individuals would have been eligible for referral due to UTS results had they not already been referred. Of those with a diagnosis of LS, age at onset of cancer ranged from 32 to 81 years.

Of the 262 individuals that had a negative screening result (i.e., all 4 MMR proteins were present on IHC), 44 were referred for to genetics although it was not indicated by UTS (24 prior to UTS and 20 after UTS results were available). In addition, of the 35 who showed loss of at least one MMR proteins by IHC but had *BRAF* V600E or *MLH1* hypermethylation present, 10 were referred to genetics (four prior to UTS and six after UTS results were available). Of these 54 referred to genetics, 32 (59%) had a visit with genetics and 24 (44%) underwent germline genetic testing for LS. Only one of the individuals who underwent genetic testing (4%) was diagnosed with LS; the individual had loss of *MLH1* on IHC and *BRAF* V600E was present in reflex testing but had been referred to genetic testing prior to IHC and was found to have a pathogenic variant in *MSH6*. Because of the inconsistencies between this individual's LS diagnosis, the IHC, and reflex results, it is suspected that there was an error in IHC results. Laboratory services declined a request for repeat testing to follow up on this inconsistency. A variant of unknown significance (VUS) in *MSH2* was detected in a second case (no MMR protein loss on IHC).

Among the 313 individuals with CRC with IHC results, 15 cases received a positive screen on IHC and were negative for *BRAF* V600E and *MLH1* hypermethylation. Among these 15 cases, 6 underwent genetic testing and were diagnosed with LS giving a detection rate of 6/313 or 1.9% (95% CI: 0.88 – 4.12%) (see Table 1 for characteristics of these patients). This estimate focuses on the diagnosis of LS in patients with CRC who underwent genetic testing in conjunction with the current tumor screen and does not include two LS cases noted above: (1) the individual with a positive IHC screen who had received a prior diagnosis of LS and did not undergo genetic testing again and (2) the individual who had a positive IHC screen and *BRAF* V600E was present on reflex testing but was diagnosed with LS following genetic testing. The detection rate is significantly greater than the proportion of LS expected in the general population (1/279 or 0.35%), yet it is less than the expected proportion among CRC patients (3%). The detection rate is an underestimate of the sample LS prevalence.



### Universal tumor screening of EC cases


The screening and referral process of patients diagnosed with EC is summarized in Fig. 3.

One individual was eligible for referral for genetic evaluation based on a positive screen for LS. This individual was referred to genetics after IHC results were available. The patient underwent genetic testing which was negative for LS.

One individual was not screened although a biopsy sample was available. Biopsy samples were used for three of the individuals with IHC results available.

Of the 52 individuals that had a negative result for IHC (i.e., all four MMR proteins were present), seven

were referred to genetics (four prior to IHC results and three after IHC results were available). In addition, of the eight who had a positive screen by IHC but had *MLH1* hypermethylation present, five were referred to genetics (all after IHC results were available). Of these 12 referred to genetics, nine had a visit with genetics and four underwent germline genetic testing for LS. None of these individuals were diagnosed with LS. One individual with a negative screen on IHC who was referred to and had a visit with genetics was not retested; prior genetic testing was negative for LS but did detect two *MUTYH* pathogenic variants.



**Discussion**


This study assesses the effectiveness of a UTS for LS implemented in an integrated healthcare system. The UTS program contributed to the identification of 5 cases of LS out of the 426 individuals who were eligible for screening by IHC. These individuals may not have received a referral to genetics without screening positive. In addition, there was a high frequency of follow-up for individuals (80%) that screened positive and were referred to genetics, which has been reported as a considerable barrier to screening success in other health systems [40, 41].

However, opportunities for improvement were identified through this analysis. During the study period, tumor tissue resections were used for screening at KPNW, while biopsy samples are inconsistently used. In 78 of the 313 CRC patients screened by IHC, biopsy or polypectomy samples were used. In 3 of the 61 EC patients screened by IHC, biopsy samples were used. Consistent use of biopsy samples could have reduced the number of individuals who had tissue available but were not screened by IHC from 52 to as few as five individuals. The use of biopsy samples for UTS is being explored by KPNW as a result. Several studies have found

**Table 1** Characteristics of Individuals Diagnosed with LS from UTS or Referral to Genetics after a CRC Diagnosis

Case	Age at CRC Diagnosis	MMR Gene	Bethesda Guidelines	Amsterdam II Criteria
1	73	MLH1	Yes	No
2*	32	MSH2	Yes	Yes
3	81	MSH6	No	Yes
4	32	PMS2	Yes	No
5	69	PMS2	No	No
6	57	PMS2	Inconclusive	No

\* Case 2 was referred to genetics before IHC results from UTS were completed. All other individuals were referred after IHC from UTS was completed.



comparable MMR when comparing biopsy samples to tissue resections in both EC and CRC patients [42–46]. There is also evidence to support the use of biopsy samples for *BRAF* V600E testing, a part of the reflex testing for CRC patients showing a loss of MLH1 [47–49]. Using biopsy samples would also allow for LS diagnosis before surgical treatment. Knowledge of LS status could alter decision making for surgical treatment of tumors. The US Multi-Society Task Force on Colorectal Cancer (MSTF) published a set of guidelines on LS management which recommends the use of biopsy samples for this reason. [33] Extended, subtotal, or total colectomies, for example, may be recommended for patients with LS [50, 51]. Preoperative LS diagnosis would allow patients to be fully informed about their own risks and recommended surgical treatment options.

In addition to individuals with biopsy samples available that were not screened by IHC, other missed opportunities included individuals with tumor tissue available that

were not screened by IHC and individuals who screened positive that did not end up being referred to genetics. Some individuals diagnosed with CRC and EC were under the age of 50 but had a normal screening result and were not referred to genetics. UTS may not correctly identify every individual who is affected by LS [52]. For example, one individual was found to have an *MSH6* pathogenic variant because they were referred to genetics and genetic testing was ordered prior to the completion of IHC screening. In this case, there were inconsistencies with the screening results and genetic findings that are unresolved, as IHC noted a loss of MLH1 and reflex testing noted the presence of *BRAF* V600E which led to a false negative screening result. Individuals meeting other high-risk criteria, such as those with a young age of onset, may still benefit from genetic counseling for hereditary colorectal cancer. The benefit of genetic testing in this group should be further explored.

Three of the 5 cases (60%) of individuals diagnosed with LS following UTS had a pathogenic variant in *PMS2*. These results are similar to a prior study at KPNW that assessed the feasibility of a UTS program among newly diagnosed cases of CRC prior to the implementation of the UTS program. [53] The results of this prior study indicated that a higher proportion of cases diagnosed with LS after being offered tumor screening for LS had a pathogenic variant in *PMS2* compared to individuals who were diagnosed with LS after being referred for genetic counseling (selective screening) (50% vs. 22%, respectively). Given *PMS2* variants are associated with a lower penetrance and older age of onset compared to other genes associated with LS, it is most likely that they are not referred for genetic counseling based on selective screening because they do not meet high-risk criteria and may be more likely to be identified by UTS programs.

Limitations to this study include small sample sizes. Specifically, detection rates had a wide margin of error due to the limited sample size. In addition, we expect UTS for LS in the individuals diagnosed with EC to be effective at identifying LS. However, in part due to the limited number of individuals included in our analysis, the UTS program did not identify any cases of LS in this group. Similar integrated health care systems have reported UTS to be ineffective at increasing LS detection in EC patients. [54] More work should be done to explore this area. Other limitations include challenges with generalizability: KPNW is a single, integrated health care system with patients who have health insurance and reside in/around Oregon and southwest Washington.

Diagnosing LS through UTS at KPNW was one step in addressing the low proportion of individuals who are aware of their increased cancer risk. This program directly led to diagnoses for 5 individuals. There is also potential to indirectly lead to further diagnoses through cascade screening and testing: the identification and genetic testing of at-risk family members. Other health systems looking to improve LS identification in their patient population will likely encounter similar challenges to those described in this paper. It is our hope that sharing the experiences and lessons learned at KPNW may assist others during implementation or quality improvement of UTS for LS.

### Conclusions

We performed a systematic assessment of a program that screens all newly diagnosed cases of CRC and EC for Lynch syndrome in an integrated healthcare setting. This study found high rates of follow-up for confirmatory germline testing for pathogenic variants associated with LS among patients who screened positive. In addition, we identified ways that the program could be

improved, such as consistent use of biopsy samples for screening. Overall, these findings can be used to provide guidance to other healthcare systems to improve or implement such screening programs.

### Abbreviations

CRC: Colorectal cancer; EC: Endometrial cancer; EMR: Electronic medical record; IHC: Immunohistochemistry; KPNW: Kaiser Permanente Northwest; LS: Lynch syndrome; MMR: Mismatch repair; MSI: Microsatellite instability; MSTF: US Multi-Society Task Force on Colorectal Cancer; UTS: Universal tumor screening; VUS: Variant of uncertain significance

### Acknowledgements

Not applicable.

### Authors' contributions

JEH, KABG, BSW, JMZ, SG, TLK, ES, and LJ contributed to study design. LJ pulled patient data from the EMR and JMZ performed chart reviews. JEH reviewed the data. JEH, KABG, BSW, PRC, ES, and LJ contributed to results interpretation. PRC led drafting of the manuscript with all authors contributing. All authors read and approved the final manuscript.

### Funding

This work was supported by a grant from the National Human Genome Research Institute (U01HG007292; MPIs: Wilfond, Goddard), with additional support from U24HG007307 (Coordinating Center). Funding for this work was also provided by the National Cancer Institute (R01CA211723; PI: Rahm).

### Availability of data and materials

Reasonable requests for the datasets generated and/or analyzed during the current study can be sent to the corresponding author.

### Declarations

#### Ethics approval and consent to participate

This analysis was reviewed and approved by the Institutional Review Board at Kaiser Permanente Northwest.

#### Competing interests

The authors declare that they have no conflicts of interest.

#### Author details

<sup>1</sup>Department of Biostatistics, School of Public Health, University of Washington, Seattle, WA, USA. <sup>2</sup>Department of Translational and Applied Genomics, Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA. <sup>3</sup>Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA. <sup>4</sup>Treuman Katz Center for Pediatric Bioethics, Department of Pediatrics, Seattle Children's Research Institute and Hospital, University of Washington School of Medicine, Seattle, WA, USA.

Received: 4 May 2021 Accepted: 1 March 2022

Published online: 18 April 2022

### References

- Barrow E, Hill J, Evans DG. Cancer risk in Lynch Syndrome. *Fam Cancer*. 2013;12(2):229–40.
- Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. *Clin Genet*. 2009;76:1–18.
- Moreira L, Balaguer F, Lindor N, et al. Identification of Lynch syndrome among patients with colorectal cancer. *JAMA*. 2012;308:1555–65.
- Hampel H, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. *J Clin Oncol*. 2008;26(35):5783–8.
- Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. *J Clin Oncol*. 2003;21(6):1174–9.
- Peltomaki P, Vasen H. Mutations associated with HNPCC predisposition – Update of ICG-HNPCC/INSIGHT mutation database. *Dis Markers*. 2004;20(4–5):269–76.

7. Rumilla K, Schowalter KV, Lindor NM, et al. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. *J Mol Diagn*. 2011; 13:93–9.
8. Kempers MJ, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. *Lancet Oncol*. 2011;12(1): 49–55.
9. Win AK, Jenkins MA, Dowty JG, et al. Prevalence and Penetration of Major Genes and Polygenes for Colorectal Cancer. *Cancer Epidemiol Biomarkers Prev*. 2017;26(3):404–12. doi:<https://doi.org/10.1158/1055-9965.EPI-16-0693>.
10. Hampel H, de la Chapelle A. The Search for Unaffected Individuals with Lynch Syndrome: Do the Ends Justify the Means? *Cancer Prev Res January*. 2011;1(4):1–5. DOI:<https://doi.org/10.1158/1940-6207.CAPR-10-0345>.
11. Jarvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. *Gastroenterology*. 1995;108(5):1405–11.
12. Burn J, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: A double-blind, randomised, placebo-controlled trial. *The Lancet*. 2020;395(10240):1855–63. doi:[https://doi.org/10.1016/s0140-6736\(20\)30366-4](https://doi.org/10.1016/s0140-6736(20)30366-4).
13. National Comprehensive Cancer Network. (2020) Genetic/Familial High-Risk Assessment: Colorectal (version 1.2020); p. LS-1; retrieved from [https://www.nccn.org/professionals/physician\\_gls/pdf/genetics\\_colon.pdf](https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf).
14. Vasen HF, Mecklin JP, Khan PM, et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). *Dis Colon Rectum*. 1991;34:424–5.
15. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology*. 1999;116: 1453–6.
16. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. *J Natl Cancer Inst*. 1997;89:1758–62.
17. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst*. 2004;96:261–8.
18. Kastanos F, et al. Development and validation of the PREMM5 model for comprehensive risk assessment of Lynch syndrome. *J Clin Oncol*. 2017 May 10. Advance online publication. DOI:<https://doi.org/10.1200/JCO.2016.69.6120>.
19. Chen S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. *JAMA*. 2006;296(12):1479–87.
20. Barnetson RA, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. *N Engl J Med*. 2006;354(26): 2751–63.
21. Hampel H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. *Gastroenterology*. 2005;129(2):415–21.
22. Stoffel E, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. *Gastroenterology*. 2009;137(5): 1621–7.
23. Wong C, Gibbs P, Johns J, et al. Value of database linkage: are patients at risk of familial colorectal cancer being referred for genetic counselling and testing? *Intern Med J*. 2008;38:328–33.
24. Cross DS, et al. Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer. *Genet Med*. 2013;15(12):933–40.
25. Hampel H, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). *N Engl J Med*. 2005;352(18):1851–60.
26. Julie C, et al. Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. *Am J Gastroenterol*. 2008; 103(11):2825–35.
27. Perez-Carbonell L, et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. *Gut*. 2012;61(6):865–72.
28. Van Lier MG, et al. Underutilization of microsatellite instability analysis in colorectal cancer patients at high risk for Lynch syndrome. *Scand J Gastroenterol*. 2009;44(5):600–4.
29. Group EW. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. *Genet Med*. 2009;11(1):35–41.
30. Palomaki GE, et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. *Genet Med*. 2009;11(1):42–65.
31. Provenzale D, et al. Genetic/Familial High-Risk Assessment: Colorectal. 2014.
32. Syngal S, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol*. 2015; 110(2):223–62.
33. Giardiello FM, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. *Am J Gastroenterol*. 2014;109(8):1159–79.
34. Bulletins-Gynecology CoP, Oncology SoG. ACOG Practice Bulletin No. 147: Lynch syndrome. *Obstet Gynecol*. 2014;124(5):1042–54.
35. Schneider JL, Davis J, Kauffman TL, et al. Stakeholder perspectives on implementing a universal Lynch syndrome screening program: a qualitative study of early barriers and facilitators. *Genet Med*. 2016;18(2):152–61. doi: <https://doi.org/10.1038/gim.2015.43>.
36. Muller C, et al. Low Referral Rate for Genetic Testing in Racially and Ethnically Diverse Patients Despite Universal Colorectal Cancer Screening. *Clin Gastroenterol Hepatol*. 2018;16(12):1911–8. doi:<https://doi.org/10.1016/j.cgh.2018.08.038>.
37. Dicks E, Pullman D, Kao K, Macmillan A, Logan GS, Simmonds C, Etchegary H. Universal tumor screening for Lynch syndrome: Perceptions of Canadian pathologists and genetic counselors of barriers and facilitators. *Cancer Med*. 2019;8(7):3614–22. doi:<https://doi.org/10.1002/cam4.2182>.
38. Cohen SA, et al. Initiation of universal tumor screening for Lynch syndrome in colorectal cancer patients as a model for the implementation of genetic information into clinical oncology practice. *Cancer*. 2016;122:393–401. doi: <https://doi.org/10.1002/cncr.29758>.
39. Salyer CV, et al. Lynch syndrome in women with endometrial cancer: Comparison of universal and age-based strategies in a California healthcare system. *Gynecol Oncol*. 2019;154(5):206–7. doi:<https://doi.org/10.1016/j.ygyno.2019.04.479>.
40. Han J, Spigelman AD. Adherence to guidelines for the referral of patients with colorectal cancer and abnormal tumour tissue testing for assessment of Lynch syndrome. *ANZ J Surg*. 2019. doi:<https://doi.org/10.1111/ans.15054>.
41. O’Kane GM, et al. Screening for mismatch repair deficiency in colorectal cancer: data from three academic medical centers. *Cancer Med*. 2017. doi: <https://doi.org/10.1002/cam4.1025>.
42. Chapel. (2018). Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens. *Gynecologic Oncology*.
43. Shia J. (2011). Immunohistochemical Staining for DNA Mismatch Repair Proteins in Intestinal Tract Carcinoma: How Reliable are Biopsy Samples?, *Am J Surg Pathol*.
44. Kumarasinghe AP, de Boer B, Bateman AC, Kumarasinghe MP. DNA mismatch repair enzyme immunohistochemistry in colorectal cancer: a comparison of biopsy and resection material. *Pathology*. 2010;42(5):414–20. doi:<https://doi.org/10.3109/000313025.2010.493862>.
45. O’Brien O, Ryan É, Creavin B, Kelly ME, Mohan HM, Geraghty R, Winter DC, Sheahan K. Correlation of immunohistochemical mismatch repair protein status between colorectal carcinoma endoscopic biopsy and resection specimens. *J Clin Pathol*. 2018 Jul;71(7):631–6. doi:<https://doi.org/10.1136/jclinpath-2017-204946>.
46. Warrior SK, Trainer AH, Lynch AC, et al. Preoperative diagnosis of Lynch syndrome with DNA mismatch repair immunohistochemistry on a diagnostic biopsy. *Dis Colon Rectum*. 2011;54(12):1480–7. doi:<https://doi.org/10.1097/DCR.0b013e318231db1f>.
47. Roth RM, Hampel H, Arnold CA, Yearsley MM, Marsh WL, Frankel WL. A modified Lynch syndrome screening algorithm in colon cancer: BRAF immunohistochemistry is efficacious and cost beneficial. *Am J Clin Pathol*. 2015 Mar;143(3):336–43. doi: <https://doi.org/10.1309/AJCP4D7RXOBHLKJG>. PMID: 25696791.
48. Toon CW, Walsh MD, Chou A, et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. *Am J Surg Pathol*. 2013;37(10):1592–602. doi:<https://doi.org/10.1097/PAS.0b013e31828f233d>.
49. Harrigan J, Davis C, Chauhan M, Buckles D, Saeed A, Kennedy K., Bansal A. (2020). Preoperative Screening of Colorectal Cancers Is As Accurate As



- Postoperative Screening for Detection of Lynch Syndrome. *Clin Gastroenterol Hepatol*, 18(10). doi:<https://doi.org/10.1016/j.cgh.2020.05.016>.
50. Natarajan N, Watson P, Silva-Lopez E, Lynch HT. Comparison of extended colectomy and limited resection in patients with Lynch syndrome. *Dis Colon Rectum*. 2010;53:77–82.
  51. Church J. Prevention of metachronous colorectal cancer in patients with Lynch syndrome. *Dis Colon Rectum*. 2010;53:3–4.
  52. Snowsill T, Coelho H, Huxley N, Jones-Hughes T, Briscoe S, Frayling IM, Hyde C. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation. *Health technology assessment. (Winchester England)*. 2017;21(51):1–238. <https://doi.org/10.3310/hta21510>.
  53. Clarke EV, Muessig KR, Zepp J, Hunter JE, Syngal S, Acheson, ... Goddard KAB. Implementation of a Systematic Tumor Screening Program for Lynch Syndrome in an Integrated Health Care Setting. *Fam Cancer*. 2019;18(3): 317–25.
  54. Lentz SE, Salyer CV, Dontsi M, et al., Comparison of two Lynch screening strategies in endometrial cancer in a California health system, *Gynecologic Oncology*, <https://doi.org/10.1016/j.ygyno.2020.04.692>.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

